{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:57:25Z","timestamp":1778558245486,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":2632,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13311-016-0453-3","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T11:29:46Z","timestamp":1467286186000},"page":"562-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Vaccinations for Neuroinfectious Disease: A Global Health Priority"],"prefix":"10.1016","volume":"13","author":[{"given":"Emily C.","family":"Leibovitch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-016-0453-3_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2471\/BLT.07.040089","article-title":"Vaccination greatly reduces disease, disability, death and inequity worldwide","volume":"86","author":"Andre","year":"2008","journal-title":"Bull World Health Organ"},{"key":"10.1007\/s13311-016-0453-3_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ana.23988","article-title":"Novel approaches and challenges to treatment of central nervous system viral infections","volume":"74","author":"Nath","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0453-3_bib3","unstructured":"Tracey, J. Syndromic Approach to Neuroinfectious disease (ed. Kelly D Flemming, L.K.J.) (Oxford University Press, 2015)."},{"key":"10.1007\/s13311-016-0453-3_bib4","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1038\/nature16033","article-title":"Global research priorities for infections that affect the nervous system","volume":"527","author":"John","year":"2015","journal-title":"Nature"},{"key":"10.1007\/s13311-016-0453-3_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7774\/cevr.2014.3.1.58","article-title":"Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses","volume":"3","author":"Go","year":"2014","journal-title":"Clin Exp Vaccine Res"},{"key":"10.1007\/s13311-016-0453-3_bib6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMp1600297","article-title":"Zika Virus in the Americas\u2014yet another arbovirus threat","volume":"374","author":"Fauci","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-016-0453-3_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/cmi.2015.76","article-title":"Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine","volume":"13","author":"Liang","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1007\/s13311-016-0453-3_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virol.2009.06.037","article-title":"Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody","volume":"392","author":"Wahala","year":"2009","journal-title":"Virology"},{"key":"10.1007\/s13311-016-0453-3_bib9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1586\/14760584.2015.1061939","article-title":"The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis","volume":"14","author":"Erra","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1007\/s13311-016-0453-3_bib10","doi-asserted-by":"crossref","unstructured":"Hills, S.L., Rabe, I.B., Fischer, M. Japanese Encephalitis, Chapter 3: Infectious Diseases Related to Travel. http:\/\/www.cdc.gov (2015).","DOI":"10.2105\/CCDM.2745.084"},{"key":"10.1007\/s13311-016-0453-3_bib11","unstructured":"Vaccine-preventable diseases and vaccines. WHO International Travel and Health publication (2015)."},{"key":"10.1007\/s13311-016-0453-3_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1007\/s13311-016-0453-3_bib13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0028-3843(14)60113-4","article-title":"Fatal outcome of tick-borne encephalitis\u2014a case series","volume":"45","author":"Zajkowska","year":"2011","journal-title":"Neurol Neurochir Pol"},{"key":"10.1007\/s13311-016-0453-3_bib14","doi-asserted-by":"crossref","unstructured":"Veje, M. et al. Tick-Borne encephalitis sequelae at long-term follow-up: a self-reported case-control study. Acta Neurol Scand (2016).","DOI":"10.1111\/ane.12561"},{"key":"10.1007\/s13311-016-0453-3_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.21101\/cejph.a4169","article-title":"The Austrian vaccination paradox: tick-borne encephalitis vaccination versus influenza vaccination","volume":"23","author":"Kunze","year":"2015","journal-title":"Cent Eur J Public Health"},{"key":"10.1007\/s13311-016-0453-3_bib16","doi-asserted-by":"crossref","unstructured":"Karunamoorthi, K. Yellow fever encephalitis: an emerging and resurging global public health threat in a changing environment (ed. S., T.) (2013).","DOI":"10.5772\/52244"},{"key":"10.1007\/s13311-016-0453-3_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/532155a","article-title":"Fears rise over yellow fever's next move","volume":"532","author":"Butler","year":"2016","journal-title":"Nature"},{"key":"10.1007\/s13311-016-0453-3_bib18","unstructured":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2013\u2014conclusions and recommendations. Wkly Epidemiol Rec88, 201-206 (2013)."},{"key":"10.1007\/s13311-016-0453-3_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1007\/s13311-016-0453-3_bib20","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0453-3_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/erv.11.180","article-title":"Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex","volume":"11","author":"Lobigs","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1007\/s13311-016-0453-3_bib22","doi-asserted-by":"crossref","unstructured":"Barrett, P.N., Mundt, W., Kistner, O. & Howard, M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines8, 607-618 (2009).","DOI":"10.1586\/erv.09.19"},{"key":"10.1007\/s13311-016-0453-3_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004765","article-title":"Zika in the United States of America and a Fateful 1969 Decision","volume":"10","author":"Hotez","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1007\/s13311-016-0453-3_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1007\/s13311-016-0453-3_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/14760584.2016.1154459","article-title":"Edging closer towards the goal of a dengue vaccine","volume":"15","author":"Wilder-Smith","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1007\/s13311-016-0453-3_bib26","doi-asserted-by":"crossref","unstructured":"Broutet, N. et al. Zika Virus as a Cause of Neurologic Disorders. N Engl J Med (2016).","DOI":"10.1056\/NEJMp1602708"},{"key":"10.1007\/s13311-016-0453-3_bib27","unstructured":"Tripp, R.A. & Ross, T.M. Development of a Zika vaccine. Expert Rev Vaccines, 1-3 (2016)."},{"key":"10.1007\/s13311-016-0453-3_bib28","doi-asserted-by":"crossref","unstructured":"Pastula, D.M., Smith, D.E., Beckham, J.D. & Tyler, K.L. Four emerging arboviral diseases in North America: Jamestown Canyon, Powassan, chikungunya, and Zika virus diseases. J Neurovirol (2016).","DOI":"10.1007\/s13365-016-0428-5"},{"key":"10.1007\/s13311-016-0453-3_bib29","doi-asserted-by":"crossref","unstructured":"Petersen, L.R., Jamieson, D.J., Powers, A.M. & Honein, M.A. Zika virus. N Engl J Med (2016).","DOI":"10.1056\/NEJMra1602113"},{"key":"10.1007\/s13311-016-0453-3_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15585\/mmwr.mm6503e2","article-title":"Possible association between Zika virus infection and microcephaly\u2014Brazil, 2015","volume":"65","author":"Schuler-Faccini","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1007\/s13311-016-0453-3_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrneurol.2016.30","article-title":"CNS infections: Zika virus infection could trigger Guillain-Barr\u00e9 syndrome","volume":"12","author":"Malkki","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-016-0453-3_bib32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3201\/eid2006.140138","article-title":"Zika virus, French polynesia, South pacific, 2013","volume":"20","author":"Cao-Lormeau","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1007\/s13311-016-0453-3_bib33","doi-asserted-by":"crossref","unstructured":"Carteaux, G. et al. Zika virus associated with meningoencephalitis. N Engl J Med (2016).","DOI":"10.1056\/NEJMc1602964"},{"key":"10.1007\/s13311-016-0453-3_bib34","doi-asserted-by":"crossref","unstructured":"Mecharles, S. et al. Acute myelitis due to Zika virus infection. Lancet (2016).","DOI":"10.1016\/S0140-6736(16)00644-9"},{"key":"10.1007\/s13311-016-0453-3_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01249709","article-title":"Zika virus infection of the central nervous system of mice","volume":"35","author":"Bell","year":"1971","journal-title":"Arch Gesamte Virusforsch"},{"key":"10.1007\/s13311-016-0453-3_bib36","doi-asserted-by":"crossref","unstructured":"Palacios, R., Poland, G.A. & Kalil, J. Another emerging arbovirus, another emerging vaccine: targeting Zika virus. Vaccine (2016).","DOI":"10.1016\/j.vaccine.2016.03.059"},{"key":"10.1007\/s13311-016-0453-3_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","article-title":"Encephalitic alphaviruses","volume":"140","author":"Zacks","year":"2010","journal-title":"Vet Microbiol"},{"key":"10.1007\/s13311-016-0453-3_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002197","article-title":"IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety","volume":"7","author":"Guerbois","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1007\/s13311-016-0453-3_bib39","first-page":"296","article-title":"Venezuelan equine encephalitis. 1995 outbreak: clinical profile of the case with neurologic involvement","volume":"29","author":"Molina","year":"1999","journal-title":"Rev Neurol"},{"key":"10.1007\/s13311-016-0453-3_bib40","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1128\/JVI.77.17.9278-9286.2003","article-title":"Recombinant sindbis\/Venezuelan equine encephalitis virus is highly attenuated and immunogenic","volume":"77","author":"Paessler","year":"2003","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0453-3_bib41","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1128\/JVI.02297-13","article-title":"Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses","volume":"88","author":"Phillips","year":"2014","journal-title":"J Virol"},{"key":"10.1007\/s13311-016-0453-3_bib42","doi-asserted-by":"crossref","unstructured":"Smalley, C., Erasmus, J.H., Chesson, C.B. & Beasley, D.W. Status of research and development of vaccines for chikungunya. Vaccine (2016).","DOI":"10.1016\/j.vaccine.2016.03.076"},{"key":"10.1007\/s13311-016-0453-3_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4103\/0028-3886.51289","article-title":"Neurological complications of Chikungunya virus infection","volume":"57","author":"Chandak","year":"2009","journal-title":"Neurol India"},{"key":"10.1007\/s13311-016-0453-3_bib44","doi-asserted-by":"crossref","unstructured":"De Benedictis, P. et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol Med (2016).","DOI":"10.15252\/emmm.201505986"},{"key":"10.1007\/s13311-016-0453-3_bib45","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4103\/0028-3886.149394","article-title":"Paralytic rabies: MRI findings and review of literature","volume":"62","author":"Kalita","year":"2014","journal-title":"Neurol India"},{"key":"10.1007\/s13311-016-0453-3_bib46","article-title":"Estimating the global burden of endemic canine rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1007\/s13311-016-0453-3_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005483","article-title":"Cold-Adapted viral attenuation (CAVA): highly temperature sensitive polioviruses as novel vaccine strains for a next generation inactivated poliovirus vaccine","volume":"12","author":"Sanders","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1007\/s13311-016-0453-3_bib48","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/ije\/dym207","article-title":"Review of the effect of measles vaccination on the epidemiology of SSPE","volume":"36","author":"Campbell","year":"2007","journal-title":"Int J Epidemiol"},{"key":"10.1007\/s13311-016-0453-3_bib49","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jcv.2013.10.016","article-title":"Fulminant encephalitis associated with a vaccine strain of rubella virus","volume":"58","author":"Gualberto","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1007\/s13311-016-0453-3_bib50","unstructured":"Subacute sclerosing panencephalitis and measles vaccination. Wkly Epidemiol Rec (2006)."},{"key":"10.1007\/s13311-016-0453-3_bib51","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/jama.2016.1353","article-title":"Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis","volume":"315","author":"Phadke","year":"2016","journal-title":"JAMA"},{"key":"10.1007\/s13311-016-0453-3_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104169","article-title":"Encephalitis hospitalization rates and inpatient mortality in the United States, 2000\u20132010","volume":"9","author":"George","year":"2014","journal-title":"PLoS One"},{"key":"10.1007\/s13311-016-0453-3_bib53","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/bmt.2015.76","article-title":"Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know","volume":"50","author":"Ogata","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1007\/s13311-016-0453-3_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coviro.2014.09.013","article-title":"Clinical impact of primary infection with roseoloviruses","volume":"9","author":"Tesini","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1007\/s13311-016-0453-3_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0887-8994(94)90021-3","article-title":"Neurologic complications of infectious mononucleosis","volume":"10","author":"Connelly","year":"1994","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-016-0453-3_bib56","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ana.10321","article-title":"Quantitative CSF PCR in Epstein\u2013Barr virus infections of the central nervous system","volume":"52","author":"Weinberg","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-016-0453-3_bib57","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1172\/JCI57148","article-title":"HSV-2: in pursuit of a vaccine","volume":"121","author":"Johnston","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-016-0453-3_bib58","article-title":"Vaccines for preventing herpes zoster in older adults","volume":"3","author":"Gagliardi","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-016-0453-3_bib59","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jpeds.2014.06.014","article-title":"Central nervous system complications of varicella-zoster virus","volume":"165","author":"Science","year":"2014","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-016-0453-3_bib60","doi-asserted-by":"crossref","unstructured":"Johnston, C., Gottlieb, S.L. & Wald, A. Status of vaccine research and development of vaccines for herpes simplex virus prepared for WHO PD-VAC. Vaccine (2016).","DOI":"10.1016\/j.vaccine.2015.12.076"},{"issue":"Suppl. 2","key":"10.1007\/s13311-016-0453-3_bib61","doi-asserted-by":"crossref","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","article-title":"The need and challenges for development of an Epstein-Barr virus vaccine","volume":"31","author":"Cohen","year":"2013","journal-title":"Vaccine"},{"key":"10.1007\/s13311-016-0453-3_bib62","first-page":"455","article-title":"The development of prophylactic and therapeutic EBV vaccines","volume":"391","author":"Smith","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1007\/s13311-016-0453-3_bib63","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14787210.2015.1070096","article-title":"Neisseria meningitidis infection: who, when and where?","volume":"13","author":"Gianchecchi","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1007\/s13311-016-0453-3_bib64","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged >\/=10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1007\/s13311-016-0453-3_bib65","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"10.1007\/s13311-016-0453-3_bib66","author":"Wilson","year":"2015","journal-title":"Fungal infections of the central nervous system (Mayo Foundation for Medical Education and Research"},{"key":"10.1007\/s13311-016-0453-3_bib67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2014.01.014","article-title":"Vaccine immunity against fungal infections","volume":"28","author":"Nanjappa","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"10.1007\/s13311-016-0453-3_bib68","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/CVI.00036-11","article-title":"Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice","volume":"18","author":"Wozniak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1007\/s13311-016-0453-3_bib69","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3389\/fmicb.2015.00836","article-title":"Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development","volume":"6","author":"Rella","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1007\/s13311-016-0453-3_bib70","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.1965","article-title":"Cytokine response during non-cerebral and cerebral malaria: evidence of a failure to control inflammation as a cause of death in African adults","volume":"4","author":"Dieye","year":"2016","journal-title":"PeerJ"},{"key":"10.1007\/s13311-016-0453-3_bib71","unstructured":"Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec91, 33-51 (2016)."},{"key":"10.1007\/s13311-016-0453-3_bib72","doi-asserted-by":"crossref","unstructured":"Gosling, R. & von Seidlein, L. The future of the RTS,S\/AS01 malaria vaccine: an alternative development plan. PLoS Med13, e1001994 (2016).","DOI":"10.1371\/journal.pmed.1001994"},{"key":"10.1007\/s13311-016-0453-3_bib73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11011-015-9787-5","article-title":"Cerebral malaria - clinical manifestations and pathogenesis","volume":"31","author":"Hora","year":"2016","journal-title":"Metab Brain Dis"},{"key":"10.1007\/s13311-016-0453-3_bib74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mib.2016.04.006","article-title":"Malaria vaccines and human immune responses","volume":"32","author":"Long","year":"2016","journal-title":"Curr Opin Microbiol"},{"key":"10.1007\/s13311-016-0453-3_bib75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nbt1015-1015","article-title":"Landmark green light for Mosquirix malaria vaccine","volume":"33","author":"Morrison","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-016-0453-3_bib76","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0453-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-016-0453-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923009248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-016-0453-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:55:08Z","timestamp":1761807308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923009248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1878747923009248"],"URL":"https:\/\/doi.org\/10.1007\/s13311-016-0453-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccinations for Neuroinfectious Disease: A Global Health Priority","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-016-0453-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}